| 词条 | Nilvadipine |
| 释义 |
| Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 459829456 | IUPAC_name = 3-Methyl 5-propan-2-yl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate | image = Nilvadipine structure.svg | tradename = | Drugs.com = {{drugs.com|international|nilvadipine}} | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number_Ref = {{cascite|correct|??}} | CAS_number = | ATC_prefix = C08 | ATC_suffix = CA10 | PubChem = 4494 | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = DB06712 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 0214FUT37J | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D01908 | ChEMBL_Ref = {{ebicite|changed|EBI}} | ChEMBL = 517427 | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID = 4338 | C=19 | H=19 | N=3 | O=6 | molecular_weight = 385.370 g/mol | smiles = CC1=C(C(C(=C(N1)C#N)C(=O)OC)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OC(C)C | StdInChI_Ref = {{stdinchicite|changed|chemspider}} | StdInChI = 1S/C19H19N3O6/c1-10(2)28-19(24)15-11(3)21-14(9-20)17(18(23)27-4)16(15)12-6-5-7-13(8-12)22(25)26/h5-8,10,16,21H,1-4H3 | StdInChIKey_Ref = {{stdinchicite|changed|chemspider}} | StdInChIKey = FAIIFDPAEUKBEP-UHFFFAOYSA-N }} Nilvadipine is a calcium channel blocker (CCB) used for the treatment of hypertension and chronic major cerebral artery occlusion. Pathohistochemical studies have revealed that the volume of the infarction in the middle cerebral artery occlusion model could be decreased by nilvadipine. Experimental research{{third-party|section|date=December 2017}}Nilvadipine was tested in clinical trial as a possible treatment for Alzheimer's disease in Ireland by the Roskamp Institute, Florida, USA and Trinity College, Ireland.[1] Following this study, an international research consortium led by Trinity College Dublin (Ireland) in May 2011 announced the selection for funding of a large-scale European clinical trial of nilvadipine. More than 500 Alzheimer’s disease patients will participate in the multicenter phase III clinical trial designed to study the effectiveness of nilvadipine.[2]{{update inline|date=December 2017}} References1. ^{{cite press release | url = http://www.rfdn.org/news_release_090806_faq.html | publisher = Roskamp Institute | title = Roskamp Nilvadipine Clinical Trial Questions and Answers}} {{Ion channel modulators}}{{Xenobiotic-sensing receptor modulators}}{{Cardiovascular-drug-stub}}2. ^{{cite press release | url = http://www.rfdn.org/news_release_052511.html | publisher = Roskamp Institute | title = Roskamp Nilvadipine Clinical Trial Press Release}} 6 : Calcium channel blockers|Dihydropyridines|Nitriles|Nitrobenzenes|Carboxylate esters|Isopropyl esters |
| 随便看 |
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。